Alexion nabs Synageva to push further into rare diseases

6 May 2015

Alexion Pharmaceuticals (Nasdaq: ALXN) has entered into a definitive agreement to acquire fellow USA-based Synageva BioPharma (Nasdaq: GEVA) for a consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva.

This implies a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015. The acquisition will strengthen Alexion’s global leadership in developing and commercializing transformative therapies for patients with devastating and rare diseases. Synageva more than doubled to $219.50 in pre-market trading, while Alexion fell 55 to $160.05.

$8.4 billion transaction value

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK